We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Avandia Trial Leads to Call for Reviewer Independence
Avandia Trial Leads to Call for Reviewer Independence
May 12, 2010
Members of Congress are calling on the FDA to strengthen the independence of its drug safety evaluators in the wake of a Senate Finance Committee staff report questioning the approval and postmarket trial of GlaxoSmithKline’s (GSK) diabetes drug Avandia.